Do you want to read an article? Please log in or register.
Clinical, Dosimetric and Radiomic Features Predictive of Lung Toxicity After (Chemo)Radiotherapy
Lung Cancer
Related content
Lung Cancer
Recommendations for radiotherapy in patients with lung cancer and interstitial lung disease: A Delphi consensus process of the Italian association of radiotherapy and clinical oncology (AIRO)
Lung Cancer
Borghetti P, D'Angelillo R, Facheris G, Borghesi A, Bruni A, Ceruti P, Ferrari K, Filippi AR, Ramella S, Signorelli D, Pappagallo G, Ricardi U, Collaborators
doi: 10.1016/j.lungcan.2025.108807
Lung Cancer
Tumor-Agnostic Circulating Tumor DNA Analysis as a Comprehensive Predictive Biomarker of Recurrence after Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer
Clin Lung Cancer
Nakamura M, Kageyama SI, Hirata H, Ohira M, Sakai SA, Hakozaki Y, Hojo H, Fujisawa T, Yamashita R, Haeno H, Kanai A, Suzuki Y, Yamaguchi M, Tsuchihara K, Zenda S
doi: 10.1016/j.cllc.2025.09.013
Further Publications
Optimizing clinical strategies for nutritional and immune indices prediction of chronic lung diseases: a cross-sectional study from NHANES 2007-2012
Ther Adv Respir Dis
He S, Chen C, Hao J, Shu Y, Yu C, Liu X, Wu X, Luo N, Zhou W, Zha Z
doi: 10.1177/17534666261432503
COMMENTED
Interstitial Lung Disease
ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease. Developed by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR)Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG)
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended and commented by
Dr Marcus Hesse, Faculty Member
Eur Respir J
Antoniou KM, Distler O, Gheorghiu AM, Moor CC, Vikse J, Bizymi N, Galetti I, Brown G, Bargagli E, Allanore Y, Corte TJ, Dieudé P, Cottin V, Fisher BA, Fabre A, Giles JT, Kreuter M, Lundberg IE, Poletti V, Maurer B, Renzoni EA, Müller-Ladner U, Strek ME, Sverzellati N, Studenic P, Mohammed J, Nagavci B, Stamm T, Tonia T, Crestani B, Hoffmann-Vold AM
doi: 10.1183/13993003.02533-2024
Lung Cancer
Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials
Lung Cancer
Zhou DD, Lord SJ, Lin FP, Cooper WA, Zaheed M, Simes RJ, John T, Lee CK
doi: 10.1016/j.lungcan.2025.108891
RECOMMENDED
Interstitial Lung Disease
Clinical utility of lung biopsy in fibrotic interstitial lung disease
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Am J Respir Crit Care Med
Mor E, Piciucchi S, Ravaglia C, Aronson K, Poletti V, Hariri LP, Khor YH, Churg A, Collins B, Fabre A, Adegunsoye A, Chung J, Cooper WA, Cottin V, Dotan Y, Hague C, Inoue Y, Jacob J, Martinez F, Podolanczuk AJ, Tomassetti S, Wells AU, Wijsenbeek MS, Yasufuku K, Dominy L, Mcdonald J, Sangari S, Ryerson CJ
doi: 10.1093/ajrccm/aamaf123
Lung Cancer
Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer: A Practical Multidisciplinary Approach to Challenging Scenarios from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee
J Thorac Oncol
Zhu H, Al Saifi S, Bahig H, Cooper A, Abrão FC, Corrales L, Faivre-Finn C, Filippi AR, Fitzgerald B, Khosla D, Lam VK, Le X, Menezes V, Newsom-Davis T, Qin A, Putora PM, Munoz-Schuffenegger P, Siva S, Yu NY, Louie AV
doi: 10.1016/j.jtho.2025.11.006
RECOMMENDED
Lung Cancer
Clinical Outcomes of Compound EGFR Mutations in Non-Small Cell Lung Cancer: A National, Retrospective, Multicenter Study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Atlagh L, Toublanc AC, Roch B, Marinello A, Ruuth-Praz J, Cousin S, Chouaid C, Basset C, Evrard S, Duruisseaux M, Girard N, Durand K, Mazières J, Brindel A
doi: 10.1016/j.cllc.2025.06.005
Lung Cancer
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration
Lancet Respir Med
Dingemans AC, Opitz I, Brunelli A, Remon J, Hendriks LEL, Edwards J, Faivre-Finn C, Reguart N, Smit EF, Levy A, Sanchez-Lorente D, Trujillo JC, Filippi AR, Stathopoulos K, Blum TG, Guckenberger M, Popat S, De Angelis R, Hofman P, von der Thüsen J, Hartemink KJ, Petersen RH, Ruffini E, Dickhoff C, Houda I, Prisciandaro E, De Ruysscher D, Derks J, Bahce I, Mariolo A, Besse B, Xenophontos E, Giaj Levra N, van Schil P, Brandão M, Berghmans T
doi: 10.1016/S2213-2600(26)00051-2